Public Companies
Psyched: Three Noteworthy Psychedelics M&As, Colorado’s Regulations, Exclusive Financing & More
Cybin’s Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety
Psychedelics biotech Cybin (NYSE: CYBN) and UK-based Small…
Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety
Psychedelics biotech Cybin (NYSE: CYBN) and UK-based Small Pharma (OTCMKTS: DMTTF) announced their definitive arrangement agreement for Cybin’s acquisition of all Small Pharma’s issued and outstanding securities. The deal has already been unanimously approved by both companies’ board of directors and will next face Cybin’s shareholders meeting on or about October 12. Read more HERE.Second Psychedelics Merger Of The Week: Silo Wellness To Buy Jamaica-Based Business For $31.9M
Silo Wellness (OTCMKTS: SILFF) has confirmed its intention to acquire all issued and outstanding securities of NUGL Inc./Kaya Group (OTCMKTS: NUGL) in an arms-length transaction valued at $31.9 (CA$43.3) million. The news was anticipated by a recent business partnership. The deal’s number reflects the combined market cap of both companies, NUGL shares valued at $0.0344 and Silo’s at $0.0147 currently (they have both entered into a trading halt as of today.) Read more HERE.Mindset Pharma's $60M Acquisition, Otsuka's Leap Into Next-Gen Psychiatry Solutions
Canadian next-generation psychedelics developer Mindset Pharma (OTCMKTS: MSSTF) has entered into a definitive agreement by which Otsuka America Inc., the U.S. arm of Otsuka Pharmaceutical Co., would acquire all its outstanding shares in an all-cash transaction for approximately $60 (CA$80) million. Otsuka Pharmaceutical is part of Tokyo-headquartered Otsuka Holdings (OTCMKTS: OTSKF). Read more HERE.Colorado's Psychedelic Future Unfolds: Regulators Host Community Meetings
Representatives of the Colorado Natural Medicine Division will host five “listening sessions” throughout September and October to engage ... Full story available on Benzinga.com dmt psychiatry psychedelic therapeutics depression anxiety psychedelics financing shares trading deal cybin mindset pharma mindset psyched silo small pharma
-
Psychedelics1 week agoAlgernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Psychedelics1 week agoRevive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
-
Law & Regulation1 week agoTryp Therapeutics merger with Exopharm approved by shareholders
-
Psilocybin1 week agoPassover Perspectives: Psychedelics, Moses, and the Burning Bush
-
Psychedelics1 week agoatai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
-
Psychedelics1 week agoSilo Pharma Announces Positive Results for Intranasal PTSD Treatment
-
Psilocybin1 week agoPsilocybin and Meditation: Unlocking the Potential for Enhancing Insightfulness
-
Psilocybin1 week ago
Psilocybin and Meditation: Unlocking the Potential for Enhancing Insightfulness